A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Explore The Safety And Therapeutic Potential Of Cannabinoids As An Adjunct For Reducing Pain (Carp)- TCH

Exclusion criteria

• 1. Current and unwilling to stop use of cannabis/marijuana and any other cannabinoids (CBD), including over the counter CBD products. 2. Known allergic reactions to cannabis, CBD, THC, or components of the study interventions. 3. Have Blood Urea Nitrogen or Creatinine levels outside the normal range, or other clinically significant laboratory abnormalities 4. Current use of automated external defibrillator (AED) 5. Chronic daily opioid use and any chronic pain or frequently reoccurring pain condition, other than endometriosis, that is treated with opioids for \> 14 days per month 6. Women with a BMI \> 35 kg/m2 7. Current use of barbiturates, benzodiazepines, ethanol, lithium, buspirone, muscle relaxants which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 8. Current use of amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, or desipramine, within 3 months of randomization 9. Treatment with another investigational drug or other intervention within 3 months of the screening visit. 10. Pregnancy, plans to become pregnant, or lactation. 11. Any interventional pain procedures within 6 weeks prior to screening or at any point during study enrollment. 12. Surgical intervention or introduction/increased dose of an opioid or analgesic regimen at any point during study enrollment 13. Implanted spinal cord or dorsal root ganglion stimulator for pain treatment. 14. Meets DSM-V criteria for a current major psychiatric illness, such as bipolar disorder, or psychosis which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 15. Have a history of substance abuse or dependence which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 16. Have an increased risk of suicide that necessitates inpatient treatment or warrants therapy excluded by the protocol, and/or current suicidal plan, per investigator clinical judgement, based on interview and defined on the Columbia Suicidality Severity Rating Scale (C-SSRS). 17. Have a history of seizures which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 18. Have uncontrolled renal, hepatic, or other systemic disorders that in the opinion of the clinician may jeopardize the patient's safe participation in this study. 19. Have a history of cardiac disorders which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 20. Myocardial infarction or stroke in the previous 6 months. 21. Resting heart rate of \> 120 or Systolic blood pressure \> 140 mm Hg, or diastolic blood pressure \> 90 mm Hg. 22. Any uncontrolled communicable disease (e.g., HIV/AIDS, tuberculosis, COVID, etc.) which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 23. Have any other illness, condition, or use of medications, which in the opinion of the P.I. and/or the admitting clinician would preclude the safe and/or successful completion of the study. 24. Have ECG abnormalities at screening including but not limited to bradycardia (less than 55 beats per minute); prolonged QTc interval (greater than 450 msec); Wolff-Parkinson White syndrome; wide complex tachycardia; 2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle branch block. 25. Have chronic alcohol use (defined as greater then 3 drinks per day, averaged over one week) 26. Known history of or suspected breast cancer on screening physical exam 27. Current use of a progestin-containing contraceptive implant